Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Franklin Covey Co. provides training and consulting services in the areas of execution, sales performance, productivity, customer loyalty, and educational improvement for organizations and individuals worldwide. The company operates through three segments: Direct Offices, International Licensees, and Education Practice. It also provides a suite of individual-effectiveness and leadership-development training and products. The company was incorporated in 1983 and is headquartered in Salt Lake City, Utah.

Franklin Covey Co.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DRAPER, UTAH--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT, ANNOUNCED TODAY THAT THE CONFERENCE CALL TO REVIEW THE COMPANY'S FIRST QUARTER 2026 FINANCIAL RESULTS WILL TAKE PLACE ON WEDNESDAY, JANUARY 7, 2026, AT 5:00 P.M. ET (3:00 P.M. MT). THE COMPANY'S FINANCIAL RESULTS ARE EXPECTED TO BE RELEASED AFTER THE CLOSE OF THE MARKET ON WEDNESDAY, JANUARY 7, 2026. INTERESTED PERSONS MAY ACCESS A LIVE WEBCAST HTTPS://EDGE.MEDIA-SERVER.COM/MMC/P/PF.

FRANKLIN COVEY TO REPORT FIRST QUARTER FISCAL 2026 RESULTS

SALT LAKE CITY--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT THAT CREATES AND DISTRIBUTES WORLD-CLASS SOLUTIONS, INCLUDING CONTENT, TRAINING, PROCESSES, AND TOOLS THAT ORGANIZATIONS AND INDIVIDUALS USE TO ACHIEVE SYSTEMIC CHANGES IN HUMAN BEHAVIOR TO TRANSFORM THEIR RESULTS, TODAY ANNOUNCED THAT IT IS ENTERING INTO A $20 MILLION 10B5-1 TRADING PLAN (THE PLAN) TO FACILITATE THE REPURCHASE OF THE COMPANY'S COMMON STOCK UNDER ITS EXISTING $50.

FRANKLIN COVEY CO. ENTERS INTO A $20 MILLION 10B5-1 TRADING PLAN TO REPURCHASE COMMON STOCK UNDER EXISTING $50 MILLION AUTHORIZATION

SALT LAKE CITY--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT THAT CREATES AND DISTRIBUTES WORLD-CLASS CONTENT, TRAINING, PROCESSES, AND TOOLS THAT ORGANIZATIONS AND INDIVIDUALS USE TO ACHIEVE SYSTEMIC CHANGES IN HUMAN BEHAVIOR TO TRANSFORM THEIR RESULTS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED AUGUST 31, 2025. FOURTH QUARTER FISCAL 2025 FINANCIAL OVERVIEW THE COMPANY'S CONSOLIDATED REVENUE FOR Q4 FY.

FRANKLIN COVEY REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL FISCAL 2025

SALT LAKE CITY--(BUSINESS WIRE)-- #AI--FRANKLINCOVEY IMPACT CONFERENCE TO FEATURE TOP AUTHORS, MEL ROBBINS, JAMES PATTERSON, PATRICK LEDDIN, STEPHEN M. R. COVEY, AND AN EXPERT AI PANEL.

GLOBAL FRANKLINCOVEY IMPACT CONFERENCE TO FEATURE MEL ROBBINS, AUTHOR OF THE LET THEM THEORY, JAMES PATTERSON AND PATRICK LEDDIN, CO-AUTHORS OF DISRUPT EVERYTHING AND WIN, STEPHEN M. R. COVEY, AUTHOR OF TRUST & INSPIRE, AND AN EXPERT AI PANEL

DRAPER, UTAH--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT, ANNOUNCED TODAY THAT THE CONFERENCE CALL TO REVIEW THE COMPANY'S FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS WILL TAKE PLACE ON WEDNESDAY, NOVEMBER 5, 2025, AT 5:00 P.M. ET (3:00 P.M. MT). THE COMPANY'S FINANCIAL RESULTS ARE EXPECTED TO BE RELEASED AFTER THE CLOSE OF THE MARKET ON WEDNESDAY, NOVEMBER 5, 2025. INTERESTED PERSONS MAY ACCESS A LIVE WEBCAST HTTPS://EDGE.MEDIA-.

FRANKLIN COVEY TO REPORT FOURTH QUARTER AND YEAR-END FISCAL 2025 RESULTS

SALT LAKE CITY--(BUSINESS WIRE)-- #AGEOFDISRUPTION--FRANKLINCOVEY LAUNCHES DISRUPT EVERYTHING: INNOVATE FOR IMPACT, BASED ON THE NEW YORK TIMES BESTSELLING BOOK BY JAMES PATTERSON AND PATRICK LEDDIN.

FRANKLINCOVEY LAUNCHES DISRUPT EVERYTHING: INNOVATE FOR IMPACT, BASED ON THE NEW YORK TIMES BESTSELLING BOOK BY JAMES PATTERSON AND PATRICK LEDDIN, DISRUPT EVERYTHING AND WIN

SALT LAKE CITY--(BUSINESS WIRE)-- #ALLACCESSPASS--FRANKLINCOVEY LAUNCHES WRITING FOR RESULTS: A PRACTICAL FRAMEWORK FOR EFFECTIVE WRITING.

FRANKLINCOVEY LAUNCHES WRITING FOR RESULTS: A PRACTICAL FRAMEWORK FOR EFFECTIVE WRITING

SALT LAKE CITY--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT THAT CREATES AND DISTRIBUTES WORLD-CLASS SOLUTIONS, INCLUDING CONTENT, TRAINING, PROCESSES, AND TOOLS THAT ORGANIZATIONS AND INDIVIDUALS USE TO ACHIEVE SYSTEMIC CHANGES IN HUMAN BEHAVIOR TO TRANSFORM THEIR RESULTS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED REPLENISHING THE COMPANY'S AUTHORIZATION TO REPURCHASE UP TO AN AGGREGATE AMOUNT OF $50 MILLION OF ITS OUTSTANDI.

FRANKLIN COVEY CO. ANNOUNCES REPLENISHMENT OF SHARE REPURCHASE PROGRAM UP TO $50 MILLION AND ADOPTION OF RULE 10B5-1 TRADING PLAN

SOUTH SAN FRANCISCO, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- ALLOGENE THERAPEUTICS, INC.(NASDAQ: ALLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING THE DEVELOPMENT OF ALLOGENEIC CAR T (ALLOCAR T) PRODUCTS FOR CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT IT HAS SELECTED STANDARD FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) AS THE LYMPHODEPLETION REGIMEN TO BE USED IN ITS ALPHA3 STUDY EVALUATING CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE CONSOLIDATION FOR LARGE B-CELL LYMPHOMA (LBCL). THIS LYMPHODEPLETION REGIMEN SELECTION WAS MADE IN CONJUNCTION WITH THE ALPHA3 DATA AND SAFETY MONITORING BOARD (DSMB) AND STEERING COMMITTEE AND FOLLOWING CONSULTATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).

ALLOGENE THERAPEUTICS MOVES FORWARD WITH STANDARD FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) LYMPHODEPLETION REGIMEN IN THE ALPHA3 TRIAL FOR CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) IN FIRST-LINE CONSOLIDATION FOR LARGE B-CELL LYMPHOMA

SALT LAKE CITY--(BUSINESS WIRE)--FRANKLIN COVEY CO. (NYSE: FC), A LEADER IN ORGANIZATIONAL PERFORMANCE IMPROVEMENT THAT CREATES AND DISTRIBUTES WORLD-CLASS CONTENT, TRAINING, PROCESSES, AND TOOLS THAT ORGANIZATIONS AND INDIVIDUALS USE TO ACHIEVE SYSTEMIC CHANGES IN HUMAN BEHAVIOR TO TRANSFORM THEIR RESULTS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD FISCAL 2025 QUARTER, ENDED MAY 31, 2025. THIRD QUARTER FISCAL 2025 FINANCIAL RESULTS THE COMPANY'S CONSOLIDATED REVENUE FOR Q3 FY2025 WAS.

Franklin Covey Co.

FC

Price

Financial Reports

No items found.

Press Releases

Franklin Covey Co.

FC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

FC